Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) EBT (2017 - 2025)

Crinetics Pharmaceuticals has reported EBT over the past 9 years, most recently at -$122.6 million for Q4 2025.

  • For Q4 2025, EBT fell 52.16% year-over-year to -$122.6 million; the TTM value through Dec 2025 reached -$465.0 million, down 56.2%, while the annual FY2025 figure was -$465.1 million, 56.12% down from the prior year.
  • EBT for Q4 2025 was -$122.6 million at Crinetics Pharmaceuticals, up from -$130.1 million in the prior quarter.
  • Over five years, EBT peaked at -$22.9 million in Q1 2021 and troughed at -$130.1 million in Q3 2025.
  • A 5-year average of -$62.1 million and a median of -$53.4 million in 2023 define the central range for EBT.
  • Biggest five-year swings in EBT: fell 20.23% in 2023 and later tumbled 69.33% in 2025.
  • Year by year, EBT stood at -$30.8 million in 2021, then plummeted by 48.18% to -$45.7 million in 2022, then fell by 22.53% to -$55.9 million in 2023, then plummeted by 44.08% to -$80.6 million in 2024, then plummeted by 52.16% to -$122.6 million in 2025.
  • Business Quant data shows EBT for CRNX at -$122.6 million in Q4 2025, -$130.1 million in Q3 2025, and -$115.7 million in Q2 2025.